December 7, 2018
4 minute read

NOL Approvals Top $1 Billion as Program Celebrates its 20th Anniversary

48 Companies Approved to Share $60 Million

TRENTON (December 7, 2018) – The New Jersey Economic Development Authority (EDA) today announced that it has approved more than $1 billion in funding for over 540 technology and life sciences companies through the Technology Business Tax Certificate Transfer Program, more commonly known as the Net Operating Loss (NOL) Program, since the program’s inception 20 years ago.

Heralded as a lifeline for companies going through unprofitable times, the NOL Program enables eligible technology and life-sciences companies to sell New Jersey net operating losses and unused research and development tax credits to unrelated profitable corporations for cash. The cash can then be used for working capital or to fund research. The EDA and the New Jersey Department of Treasury’s Division of Taxation administer the program.

This year, 48 companies were approved to share $60 million through the NOL Program, the maximum amount of funding allocated for the program. Of those, 14 companies are new to the program, a 27 percent increase from last year. Sixteen companies previously leveraged additional EDA resources, such as New Jersey Founders & Funders, the Angel Investor Tax Credit Program, and the Edison Innovation Fund. The EDA saw an 18 percent increase in the number of applications this year as compared to 2017, and the highest number since 2014. This year, the average award was $1.25 Million.  

“The vision Governor Phil Murphy has laid out for the innovation economy reiterates the need for tools like the NOL Program to fuel technology and life sciences companies’ growth from their earliest stages through commercialization and beyond,” EDA Chief Executive Officer (CEO) Tim Sullivan. “This year’s roster of participating companies is doing promising work, and it will be fascinating to watch as they further develop their contributions to the state’s vast body of innovation.”

Participating companies hail from across New Jersey’s technology and life sciences industry. However, there was a particularly strong showing this year from the state’s biotechnology and health technology sectors, including the following first-time participants:

Celsion Corporation is a biopharmaceutical company that develops cancer treatments, including targeted chemotherapies and immunotherapies. The company’s clinical stage products focus on combatting liver and ovarian cancer. Celsion, which started in Maryland in 2000, relocated to Lawrenceville in 2011. The company currently employs 25 people.

“Since bringing Celsion here to tap into New Jersey’s tremendous pharmaceutical talent, I have been impressed by the array of resources the State offers life sciences companies like ours,” Celsion Chairman and CEO Michael Tardugno said. “The non-dilutive funding we received through the NOL Program will allow us to continue to bring our groundbreaking products through clinical trials and eventually to the marketplace.”  

Newark-based WellSheet Inc. applies physician-driven design and machine learning to Electronic Medical Records (EMRs) to improve the physician experience and early intervention for at-risk patients. Founded in 2015, the company currently has offices in New Jersey and New York, serving some of the largest hospitals in these states. WellSheet graduated from Newark Venture Partners’ NVP Labs program, a 10-week accelerator program, last year.

“We’re a relatively young company that has reaped the benefits of locating in New Jersey, such as access to the NVP Labs accelerator and the NOL Program,” Wellsheet CEO Craig Limoli said. “Funding from the NOL Program will allow us to build out our system and help even more doctors as they treat their patients.”

Jersey City-based TrialScope provides proven solutions designed to optimize the efficiency of clinical trial disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. TrialScope previously received support from Edison VII, an Edison Partners venture fund in which the EDA invested. 

“We’re proud to offer our products and services to large and small pharmaceutical companies throughout the world and to support them with all their clinical trial transparency and compliance needs,” TrialScope CEO Jeff Kozloff said. “We were attracted to the NOL Program because it will allow us to raise working capital without giving up equity in our company.”

About the New Jersey Economic Development Authority
The New Jersey Economic Development Authority (NJEDA) serves as the State’s principal agency for driving economic growth.  The NJEDA is committed to making New Jersey a national model for inclusive and sustainable economic development by focusing on key strategies to help build strong and dynamic communities, create good jobs for New Jersey residents, and provide pathways to a stronger and fairer economy.  Through partnerships with a diverse range of stakeholders, the NJEDA creates and implements initiatives to enhance the economic vitality and quality of life in the State and strengthen New Jersey’s long-term economic competitiveness.

To learn about the multitude of resources available to help technology and life sciences companies thrive, visit and follow @NewJerseyEDA on FacebookTwitter and LinkedIn.

Companies Approved for This Year's NOL Program:
Acuitive Technologies, Inc.AllendaleBergen
Admera Health LLC. South PlainfieldMiddlesex
Angel Medical SystemsEatontownMonmouth
Arable Labs Inc.PrincetonMercer
Bellerophon Therapeutics, Inc.WarrenSomerset
Brilliant Light Power, Inc. (f/k/a BlackLight Power)CranburyMiddlesex
Cancer Genetics, Inc.RutherfordBergen
Celsion CorporationLawrencevilleMercer
CircleBlack, Inc.KingstonMiddlesex
Connotate, Inc.New BrunswickMiddlesex
ContraVir Pharmaceuticals, Inc.EdisonMiddlesex
CorMedix Inc.Berkeley HeightsUnion
Crescenta Biosciences, Inc.UnionUnion
CytoSorbents Medical, Inc.Monmouth JunctionMiddlesex
Deltronic Crystal Industries, Inc.DoverMorris
doForms NJ, Inc.CranfordUnion
Edge TherapeuticsBerkeley HeightsUnion
Elite Laboratories, Inc.NorthvaleBergen
Engage TherapeuticsSummitUnion
Enhatch Inc.HobokenHudson
Eos Energy Storage LLCEdisonMiddlesex
Gadget Software, Inc.NewarkEssex
Hemispherx Biopharma, Inc.New BrunswickMiddlesex
Impactivate Networks, Inc.Atlantic CityAtlantic
IoTecha CorpPiscatawayMiddlesex
Matinas Biopharma NanotechnologiesBedminsterSomerset
MDx Medical, Inc.LyndhurstBergen
Miami International Holdings, Inc.PrincetonMercer
Moblty Inc.LivingstonEssex
MYOS RENS Technology Inc.Cedar KnollsMorris
Nanotech Industrial SolutionsAvenelMiddlesex
Nephros, Inc.South OrangeEssex
Ocean Power Technologies, Inc.Monroe TownshipMiddlesex
Provention Bio, Inc.OldwickHunterdon
Radius8, Inc.PrincetonMercer
Rafael Pharmaceuticals, Inc. f/k/a Cornerstone PhaNewarkEssex
Reflik, Inc.SomersetSomerset
Rive Technology, Inc.Monmouth JunctionMiddlesex
SCYNEXIS, Inc.Jersey CityHudson
Solidia TechnologiesPiscatawayMiddlesex
Soligenix, Inc.PrincetonMercer
Special Needs Ware, Inc. d/b/a OnederNewarkEssex
Svelte Medical Systems, Inc.New ProvidenceUnion
TAXIS Pharmaceuticals, Inc.Monmouth JunctionMiddlesex
TrialScope, IncJersey CityHudson
United Silicon Carbide, Inc.Monmouth JunctionMiddlesex
WellSheet Inc.NewarkEssex